Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

Josep Corominas, Victor Sapena, Marco Sanduzzi-Zamparelli, Cristina Millán, Esther Samper, Neus Llarch, Gemma Iserte, Ferràn Torres, Leonardo G. Da Fonseca, Sergio Muñoz-Martínez, Alejandro Forner, Jordi Bruix, Loreto Boix, María Reig

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.

Original languageEnglish
Article number426
Pages (from-to)1-20
Number of pages20
JournalCancers
Volume13
Issue number3
DOIs
Publication statusPublished - Feb 2021

Keywords

  • CD96
  • DNAM-1
  • Early dermatologic adverse events
  • Hepatocellular carcinoma
  • Immune cell phenotyping
  • PD-1
  • Peripheral blood mononuclear cells
  • Sorafenib
  • EOMES
  • peripheral blood mononuclear cells
  • sorafenib
  • COACTIVATION
  • TUMOR
  • immune cell phenotyping
  • ATEZOLIZUMAB
  • CD8(+) T-CELLS
  • BET
  • early dermatologic adverse events
  • IMMUNOTHERAPY
  • RECEPTORS
  • TIGIT
  • CHECKPOINTS
  • hepatocellular carcinoma

Fingerprint

Dive into the research topics of 'Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this